Skip to main content
. 2015 Mar 19;4(4):e999536. doi: 10.1080/2162402X.2014.999536

Figure 5.

Figure 5.

Prevalence and subtype of CD20+ T-cells in patients with ovarian cancer. PBMCs (A) or ascites fluid cells (B) from patients with ovarian cancer were stained using anti-CD3-PE, anti-CD20-FITC, anti-CD45RO-APC and anti-CCR7-PerCP-Cy5.5 mAbs and analyzed using flow cytometry. (C-D) Percentages (C) and subset distribution (D) of CD20+ T cells in peripheral blood of healthy volunteers, peripheral blood of patients with ovarian cancer and in ascites fluid of ovarian cancer. Data were analyzed as described in the legend to Fig. 1.